Effect of Nanomicelle Curcumin in pediatric asthma

Phase 2

Recruiting

• Conditions: asthma.; Mild persistent asthma; J45.3

• Registration Number: IRCT20191221045837N3
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 November 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

Pediatric patients admitted to allergy subspecialized clinic of Akbar hospital
6-12 years old
With mild persistant asthma based on Global Initiative for Asthma (GINA) 2019 guideline
Informed consent of patient/caregiver

Exclusion Criteria

Patients with pulmunary infection
Patients with underlying cardiac, hepatic, biliary, renal, or gastrointestinal diseases or allergic rhinitis
Patients with smoker parents
Patients taking anticoagolant or antiplatelet medications
Patients with diabetes

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patients' clinical signs score in asthma control questionnaire (c-ACT). Timepoint: At baseline and end of the study (end of the second month). Method of measurement: Asthma Control Questionnaire.;Maximal Mid-Expiratory Flow rate (MMEF25-75). Timepoint: At baseline and end of the study (end of the second month). Method of measurement: spirometry test.;Value of Forced expiratory volume in one second (FEV1). Timepoint: At baseline and end of the study (end of the second month). Method of measurement: spirometry test.;Value of Forced Vital Capacity (FVC). Timepoint: At baseline and end of the study (end of the second month). Method of measurement: spirometry test.;Ratio of Forced expiratory volume in one second (FEV1)/Value of Forced Vital Capacity (FVC). Timepoint: At baseline and end of the study (end of the second month). Method of measurement: spirometry test.